

Adrian V S Hill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7612716/publications.pdf>

Version: 2024-02-01

275
papers

38,420
citations

3515

90
h-index

3394

183
g-index

288
all docs

288
docs citations

288
times ranked

40168
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. <i>Molecular Therapy</i> , 2022, 30, 2024-2047. | 3.7 | 14 |
| 2 | Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. <i>Frontiers in Immunology</i> , 2022, 13, 795463. | 2.2 | 6 |
| 3 | Virus-like particle vaccines. , 2022, , 163-176. | | 0 |
| 4 | CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, . | 2.3 | 6 |
| 5 | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, . | 2.3 | 26 |
| 6 | Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. <i>Nature Communications</i> , 2022, 13, 1818. | 5.8 | 28 |
| 7 | A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, . | 4.2 | 28 |
| 8 | Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers. <i>Science</i> , 2022, 377, 72-79. | 6.0 | 13 |
| 9 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111. | 6.3 | 3,887 |
| 10 | Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288. | 15.2 | 265 |
| 11 | T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278. | 15.2 | 473 |
| 12 | Malaria is a cause of iron deficiency in African children. <i>Nature Medicine</i> , 2021, 27, 653-658. | 15.2 | 35 |
| 13 | COVID-19 vaccines for rapid global impact. <i>BJU International</i> , 2021, 127, 137-139. | 1.3 | 1 |
| 14 | Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination. <i>EMBO Molecular Medicine</i> , 2021, 13, e13390. | 3.3 | 7 |
| 15 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891. | 6.3 | 979 |
| 16 | Safety and Immunogenicity of Adenovirus and Poxvirus Vectors Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262. | 2.1 | 3 |
| 17 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362. | 6.3 | 540 |
| 18 | Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. <i>Scientific Reports</i> , 2021, 11, 10792. | 1.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1809-1818. | 6.3 | 253 |
| 20 | Dissection-independent production of <i>Plasmodium</i> sporozoites from whole mosquitoes. <i>Life Science Alliance</i> , 2021, 4, e202101094. | 1.3 | 2 |
| 21 | A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636. | 5.8 | 31 |
| 22 | Screening of viral-vectored <i>P. falciparum</i> pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites. <i>PLoS ONE</i> , 2021, 16, e0254498. | 1.1 | 2 |
| 23 | Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021, 8, e474-e485. | 2.1 | 190 |
| 24 | AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211. | 5.8 | 80 |
| 25 | Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to <i>P. falciparum</i> Transmission-Blocking Candidate Pfs25 in Humans. <i>Frontiers in Immunology</i> , 2021, 12, 732667. | 2.2 | 6 |
| 26 | Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040. | 15.2 | 900 |
| 27 | Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. <i>Nature</i> , 2021, 9, e003218. | | 10 |
| 28 | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990. | 6.3 | 214 |
| 29 | Paths and timings of the peopling of Polynesia inferred from genomic networks. <i>Nature</i> , 2021, 597, 522-526. | 13.7 | 31 |
| 30 | Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. <i>Scientific Reports</i> , 2021, 11, 20877. | 1.6 | 2 |
| 31 | Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. <i>Frontiers in Genetics</i> , 2021, 12, 719791. | 1.1 | 7 |
| 32 | Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. <i>Genes and Immunity</i> , 2020, 21, 63-70. | 2.2 | 5 |
| 33 | Vaccine innovations for emerging infectious diseases—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2020, 1462, 14-26. | 1.8 | 15 |
| 34 | Identification of antigens presented by MHC for vaccines against tuberculosis. <i>Npj Vaccines</i> , 2020, 5, 2. | 2.9 | 69 |
| 35 | Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 108-125. | 1.8 | 34 |
| 36 | Immunological considerations for SARS-CoV-2 human challenge studies. <i>Nature Reviews Immunology</i> , 2020, 20, 715-716. | 10.6 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478. | 6.3 | 2,080 |
| 38 | Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993. | 6.3 | 1,196 |
| 39 | Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, . | 4.2 | 31 |
| 40 | The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans. <i>Scientific Reports</i> , 2020, 10, 9004. | 1.6 | 9 |
| 41 | Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency. <i>BMC Medicine</i> , 2020, 18, 148. | 2.3 | 4 |
| 42 | Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 270. | 1.8 | 14 |
| 43 | Estimating the burden of iron deficiency among African children. <i>BMC Medicine</i> , 2020, 18, 31. | 2.3 | 47 |
| 44 | Native American gene flow into Polynesia predating Easter Island settlement. <i>Nature</i> , 2020, 583, 572-577. | 13.7 | 64 |
| 45 | Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928. | | 27 |
| 46 | Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. <i>Infection and Immunity</i> , 2020, 88, . | 1.0 | 7 |
| 47 | Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. <i>Scientific Reports</i> , 2020, 10, 5716. | 1.6 | 9 |
| 48 | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 816-826. | 4.6 | 182 |
| 49 | TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16479-16488. | 3.3 | 43 |
| 50 | Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. <i>Npj Vaccines</i> , 2019, 4, 44. | 2.9 | 31 |
| 51 | The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. <i>Science Advances</i> , 2019, 5, eaaw0109. | 4.7 | 20 |
| 52 | Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197. | 1.9 | 59 |
| 53 | A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 96. | 1.8 | 27 |
| 54 | Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. <i>Vaccines</i> , 2019, 7, 40. | 2.1 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. <i>Vaccines</i> , 2019, 7, 33. | 2.1 | 23 |
| 56 | Iron Status and Associated Malaria Risk Among African Children. <i>Clinical Infectious Diseases</i> , 2019, 68, 1807-1814. | 2.9 | 38 |
| 57 | Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and <i>Toxoplasma gondii</i> . <i>PLoS ONE</i> , 2019, 14, e0210407. | 1.1 | 18 |
| 58 | Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. <i>Scientific Reports</i> , 2018, 8, 3390. | 1.6 | 34 |
| 59 | Language continuity despite population replacement in Remote Oceania. <i>Nature Ecology and Evolution</i> , 2018, 2, 731-740. | 3.4 | 91 |
| 60 | Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3601-E3603. | 3.3 | 12 |
| 61 | Risk of nontyphoidal <i>Salmonella</i> bacteraemia in African children is modified by STAT4. <i>Nature Communications</i> , 2018, 9, 1014. | 5.8 | 29 |
| 62 | DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 107. | 1.0 | 7 |
| 63 | First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. <i>PLoS ONE</i> , 2018, 13, e0208328. | 1.1 | 53 |
| 64 | CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. <i>Frontiers in Immunology</i> , 2018, 9, 1660. | 2.2 | 26 |
| 65 | Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018, 10, . | 5.8 | 68 |
| 66 | Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses. <i>Scientific Reports</i> , 2018, 8, 15020. | 1.6 | 18 |
| 67 | A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006870. | 1.3 | 40 |
| 68 | Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49. | 2.9 | 51 |
| 69 | Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, 2441. | 5.8 | 69 |
| 70 | Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. <i>Vaccines</i> , 2018, 6, 50. | 2.1 | 54 |
| 71 | Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326. | 0.4 | 30 |
| 72 | Tailoring a <i>Plasmodium vivax</i> Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. <i>Infection and Immunity</i> , 2018, 86, . | 1.0 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. <i>Scientific Reports</i> , 2018, 8, 3896. | 1.6 | 15 |
| 74 | The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. <i>Journal of Immunology</i> , 2017, 198, 2006-2016. | 0.4 | 17 |
| 75 | Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. <i>Vaccine Journal</i> , 2017, 24, . | 3.2 | 20 |
| 76 | Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. <i>Science Advances</i> , 2017, 3, e1602096. | 4.7 | 46 |
| 77 | Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017, 25, 547-559. | 3.7 | 34 |
| 78 | Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. <i>Scientific Reports</i> , 2017, 7, 46482. | 1.6 | 41 |
| 79 | Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. <i>Nature Communications</i> , 2017, 8, 14946. | 5.8 | 114 |
| 80 | Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. <i>Scientific Reports</i> , 2017, 7, 46621. | 1.6 | 158 |
| 81 | ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. <i>Vaccine</i> , 2017, 35, 3780-3788. | 1.7 | 133 |
| 82 | Cryopreservation-related loss of antigen-specific IFN γ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. <i>Vaccine</i> , 2017, 35, 1898-1906. | 1.7 | 40 |
| 83 | Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 328-339. | 2.5 | 178 |
| 84 | Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032. | 1.4 | 67 |
| 85 | Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M α , β . <i>Vaccine</i> , 2017, 35, 6208-6217. | 1.7 | 27 |
| 86 | Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. <i>Scientific Reports</i> , 2017, 7, 7284. | 1.6 | 13 |
| 87 | An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. <i>Scientific Reports</i> , 2017, 7, 17011. | 1.6 | 15 |
| 88 | Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. <i>Frontiers in Immunology</i> , 2017, 8, 1551. | 2.2 | 23 |
| 89 | Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. <i>JCI Insight</i> , 2017, 2, . | 2.3 | 78 |
| 90 | Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016, 4, 27. | 2.1 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 2016, 11, e0167951. | 1.1 | 46 |
| 92 | Chronic hepatitis C viral infection subverts vaccine-induced T _H 1 cell immunity in humans. Hepatology, 2016, 63, 1455-1470. | 3.6 | 43 |
| 93 | Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine, 2016, 34, 2296-2298. | 1.7 | 28 |
| 94 | Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific Reports, 2016, 6, 20617. | 1.6 | 98 |
| 95 | Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 2016, 24, 1470-1477. | 3.7 | 52 |
| 96 | Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 2016, 41, 47-54. | 2.4 | 137 |
| 97 | Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vected Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781. | 1.9 | 96 |
| 98 | Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. American Journal of Human Genetics, 2016, 98, 1092-1100. | 2.6 | 39 |
| 99 | A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646. | 13.9 | 295 |
| 100 | Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2016, 34, 49-55. | 1.7 | 13 |
| 101 | Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2016, 16, 31-42. | 4.6 | 187 |
| 102 | Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respiratory Medicine, the, 2016, 4, 259-271. | 5.2 | 536 |
| 103 | Differential immunogenicity between HA ₂ V-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Scientific Reports, 2015, 5, 16756. | 1.6 | 36 |
| 104 | Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. Frontiers in Microbiology, 2015, 6, 965. | 1.5 | 21 |
| 105 | Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study. PLoS ONE, 2015, 10, e0123532. | 1.1 | 8 |
| 106 | Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PflUIS3, PflSA1 and PflSAP2 in Multiple Strains of Mice. PLoS ONE, 2015, 10, e0144515. | 1.1 | 5 |
| 107 | Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086. | 1.9 | 110 |
| 108 | Variants in the Mannose-binding Lectin Gene <i>MBL2</i> do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. Clinical Infectious Diseases, 2015, 61, 695-703. | 2.9 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1254-1259. | 0.6 | 5 |
| 110 | Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respiratory Medicine, 2015, 3, 53-60. | 5.2 | 166 |
| 111 | The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine, 2015, 33, 1121-1128. | 1.7 | 20 |
| 112 | Genomic modulators of gene expression in human neutrophils. Nature Communications, 2015, 6, 7545. | 5.8 | 120 |
| 113 | Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Scientific Reports, 2015, 5, 11820. | 1.6 | 49 |
| 114 | Genetic susceptibility to invasive Salmonella disease. Nature Reviews Immunology, 2015, 15, 452-463. | 10.6 | 81 |
| 115 | Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malaria Journal, 2015, 14, 33. | 0.8 | 39 |
| 116 | Searching for the human genetic factors standing in the way of universally effective vaccines. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140341. | 1.8 | 38 |
| 117 | Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726. | 9.4 | 310 |
| 118 | Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Science Translational Medicine, 2015, 7, 286re5. | 5.8 | 113 |
| 119 | Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine, 2015, 33, 3248-3255. | 1.7 | 30 |
| 120 | Workshop report: Malaria vaccine development in Europe—preparing for the future. Vaccine, 2015, 33, 6137-6144. | 1.7 | 15 |
| 121 | Profiling the host response to malaria vaccination and malaria challenge. Vaccine, 2015, 33, 5316-5320. | 1.7 | 21 |
| 122 | Progress with viral vectored malaria vaccines: A multi-stage approach involving natural immunity. Vaccine, 2015, 33, 7444-7451. | 1.7 | 53 |
| 123 | Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells. PLoS ONE, 2015, 10, e0119880. | 1.1 | 17 |
| 124 | Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain. PLoS ONE, 2014, 9, e100538. | 1.1 | 33 |
| 125 | 4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques. PLoS ONE, 2014, 9, e105520. | 1.1 | 7 |
| 126 | A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Translational Medicine, 2014, 6, 261ra153. | 5.8 | 297 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vected Vaccine Expressing Conserved Influenza A Antigens. <i>Molecular Therapy</i> , 2014, 22, 668-674. | 3.7 | 165 |
| 128 | Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475. | 3.7 | 188 |
| 129 | Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to <i>Plasmodium falciparum</i> using sporozoites administered by intramuscular injection. <i>Frontiers in Microbiology</i> , 2014, 5, 686. | 1.5 | 95 |
| 130 | Efficacy of a <i>Plasmodium vivax</i> Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic <i>Plasmodium berghei</i> Parasites. <i>Infection and Immunity</i> , 2014, 82, 1277-1286. | 1.0 | 53 |
| 131 | RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events. <i>Journal of Immunology</i> , 2014, 192, 5963-5973. | 0.4 | 38 |
| 132 | Analysis of human B cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. <i>Immunology</i> , 2014, 141, 628-644. | 2.0 | 43 |
| 133 | Towards a multi-antigen multi-stage malaria vaccine. <i>Malaria Journal</i> , 2014, 13, . | 0.8 | 7 |
| 134 | Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. <i>Vaccine Journal</i> , 2014, 21, 901-903. | 3.2 | 12 |
| 135 | Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. <i>Molecular Therapy</i> , 2014, 22, 233-238. | 3.7 | 101 |
| 136 | Combining Viral Vected and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. <i>Molecular Therapy</i> , 2014, 22, 2142-2154. | 3.7 | 68 |
| 137 | Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. <i>Molecular Therapy</i> , 2014, 22, 1992-2003. | 3.7 | 49 |
| 138 | Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. <i>Scientific Reports</i> , 2014, 4, 6154. | 1.6 | 46 |
| 139 | External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. <i>PLoS ONE</i> , 2014, 9, e97398. | 1.1 | 28 |
| 140 | Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. <i>PLoS ONE</i> , 2014, 9, e107903. | 1.1 | 65 |
| 141 | A Phase 1a Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. <i>PLoS ONE</i> , 2014, 9, e115161. | 1.1 | 48 |
| 142 | Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, 2836. | 5.8 | 256 |
| 143 | Immunogenicity and efficacy of a chimpanzee adenovirus-vecored Rift Valley Fever vaccine in mice. <i>Virology Journal</i> , 2013, 10, 349. | 1.4 | 51 |
| 144 | Identifying Recent Adaptations in Large-Scale Genomic Data. <i>Cell</i> , 2013, 152, 703-713. | 13.5 | 325 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling. <i>PLoS Pathogens</i> , 2013, 9, e1003303. | 2.1 | 70 |
| 146 | Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 340-345. | 1.9 | 53 |
| 147 | Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. <i>Journal of Immunology</i> , 2013, 190, 1135-1147. | 0.4 | 23 |
| 148 | The utility of <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment. <i>Scientific Reports</i> , 2013, 3, 1706. | 1.6 | 36 |
| 149 | Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960. | 1.1 | 80 |
| 150 | Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice. <i>PLoS ONE</i> , 2013, 8, e67888. | 1.1 | 66 |
| 151 | Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with <i>Plasmodium falciparum</i> Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. <i>PLoS ONE</i> , 2013, 8, e57726. | 1.1 | 64 |
| 152 | Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. <i>Journal of Infectious Diseases</i> , 2012, 205, 772-781. | 1.9 | 194 |
| 153 | Recombinant Viral-Vectored Vaccines Expressing <i>Plasmodium chabaudi</i> Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection. <i>Journal of Immunology</i> , 2012, 188, 5041-5053. | 0.4 | 29 |
| 154 | Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. <i>Science Translational Medicine</i> , 2012, 4, 115ra2. | 5.8 | 257 |
| 155 | Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. <i>Clinical Infectious Diseases</i> , 2012, 55, 19-25. | 2.9 | 224 |
| 156 | Bayesian refinement of association signals for 14 loci in 3 common diseases. <i>Nature Genetics</i> , 2012, 44, 1294-1301. | 9.4 | 469 |
| 157 | ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368. | 3.7 | 196 |
| 158 | Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. <i>Travel Medicine and Infectious Disease</i> , 2012, 10, 192-196. | 1.5 | 10 |
| 159 | Evolution, revolution and heresy in the genetics of infectious disease susceptibility. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012, 367, 840-849. | 1.8 | 117 |
| 160 | Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 706-714. | 1.4 | 73 |
| 161 | Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. <i>Molecular Therapy</i> , 2012, 20, 1633-1647. | 3.7 | 37 |
| 162 | Fusion of the <i>Mycobacterium tuberculosis</i> Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. <i>PLoS ONE</i> , 2012, 7, e33555. | 1.1 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen. PLoS ONE, 2012, 7, e42388. | 1.1 | 9 |
| 164 | T Cell Responses Induced by Adenoviral Vected Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. PLoS ONE, 2012, 7, e44943. | 1.1 | 23 |
| 165 | A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. PLoS ONE, 2012, 7, e48322. | 1.1 | 107 |
| 166 | Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. Science Translational Medicine, 2012, 4, 115ra1. | 5.8 | 356 |
| 167 | Human genetic susceptibility to infectious disease. Nature Reviews Genetics, 2012, 13, 175-188. | 7.7 | 413 |
| 168 | Coated microneedle arrays for transcutaneous delivery of live virus vaccines. Journal of Controlled Release, 2012, 159, 34-42. | 4.8 | 141 |
| 169 | Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnology and Bioengineering, 2012, 109, 719-728. | 1.7 | 44 |
| 170 | Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS ONE, 2012, 7, e31208. | 1.1 | 157 |
| 171 | Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. PLoS ONE, 2012, 7, e38434. | 1.1 | 66 |
| 172 | A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 2012, 7, e40385. | 1.1 | 301 |
| 173 | Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection. PLoS ONE, 2012, 7, e50447. | 1.1 | 23 |
| 174 | The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature Communications, 2011, 2, 601. | 5.8 | 233 |
| 175 | A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine, 2011, 29, 7514-7522. | 1.7 | 46 |
| 176 | Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vected Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS ONE, 2011, 6, e20977. | 1.1 | 45 |
| 177 | Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. PLoS ONE, 2011, 6, e22442. | 1.1 | 68 |
| 178 | Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology, 2011, 23, 377-382. | 2.4 | 188 |
| 179 | Vaccines and global health. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2733-2742. | 1.8 | 25 |
| 180 | CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria. Journal of Immunology, 2011, 187, 1347-1357. | 0.4 | 110 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. <i>Journal of Immunology</i> , 2011, 187, 3738-3750. | 0.4 | 41 |
| 182 | Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. <i>Molecular Therapy</i> , 2011, 19, 2269-2276. | 3.7 | 156 |
| 183 | Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. <i>Clinical Infectious Diseases</i> , 2011, 52, 1-7. | 2.9 | 424 |
| 184 | Vaccines against malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 2806-2814. | 1.8 | 165 |
| 185 | The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. <i>Journal of Immunology</i> , 2011, 187, 2602-2616. | 0.4 | 55 |
| 186 | Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. <i>PLoS ONE</i> , 2011, 6, e22271. | 1.1 | 84 |
| 187 | Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass. <i>Science Translational Medicine</i> , 2010, 2, 19ra12. | 5.8 | 139 |
| 188 | Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. <i>Nature Genetics</i> , 2010, 42, 739-741. | 9.4 | 332 |
| 189 | Prime-boost vectored malaria vaccines: Progress and prospects. <i>Hum Vaccin</i> , 2010, 6, 78-83. | 2.4 | 184 |
| 190 | An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. <i>Human Molecular Genetics</i> , 2010, 19, 720-730. | 1.4 | 23 |
| 191 | Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 ⁺ T-Cell Responses. <i>Infection and Immunity</i> , 2010, 78, 145-153. | 1.0 | 178 |
| 192 | Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. <i>Vaccine</i> , 2010, 29, 256-265. | 1.7 | 67 |
| 193 | Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines. <i>Journal of Immunology</i> , 2010, 185, 7583-7595. | 0.4 | 76 |
| 194 | Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis-infected Individuals. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 724-733. | 2.5 | 107 |
| 195 | Consanguinity and susceptibility to infectious diseases in humans. <i>Biology Letters</i> , 2009, 5, 574-576. | 1.0 | 62 |
| 196 | Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. <i>Cell Host and Microbe</i> , 2009, 5, 95-105. | 5.1 | 65 |
| 197 | Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. <i>Vaccine</i> , 2009, 27, 5589-5598. | 1.7 | 19 |
| 198 | Jenner reborn: a new vaccine institute. <i>Lancet, The</i> , 2009, 373, 445-446. | 6.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i> . <i>European Journal of Immunology</i> , 2008, 38, 732-741. | 1.6 | 95 |
| 200 | Effective induction of high-titer antibodies by viral vector vaccines. <i>Nature Medicine</i> , 2008, 14, 819-821. | 15.2 | 148 |
| 201 | Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. <i>PLoS ONE</i> , 2008, 3, e1493. | 1.1 | 99 |
| 202 | Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified <i>Vaccinia virus Ankara</i> (MVA). <i>PLoS ONE</i> , 2008, 3, e1638. | 1.1 | 87 |
| 203 | Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. <i>PLoS ONE</i> , 2008, 3, e2921. | 1.1 | 45 |
| 204 | The Induction and Persistence of T Cell IFN- γ Responses after Vaccination or Natural Exposure Is Suppressed by <i>Plasmodium falciparum</i> . <i>Journal of Immunology</i> , 2007, 179, 4193-4201. | 0.4 | 88 |
| 205 | Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. <i>Infection and Immunity</i> , 2007, 75, 5819-5826. | 1.0 | 43 |
| 206 | Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. <i>PLoS ONE</i> , 2007, 2, e707. | 1.1 | 57 |
| 207 | A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. <i>Vaccine</i> , 2006, 24, 2850-2859. | 1.7 | 86 |
| 208 | PTPN22 and invasive bacterial disease. <i>Nature Genetics</i> , 2006, 38, 499-500. | 9.4 | 54 |
| 209 | Pre-erythrocytic malaria vaccines: towards greater efficacy. <i>Nature Reviews Immunology</i> , 2006, 6, 21-32. | 10.6 | 125 |
| 210 | Aspects of Genetic Susceptibility to Human Infectious Diseases. <i>Annual Review of Genetics</i> , 2006, 40, 469-486. | 3.2 | 244 |
| 211 | A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. <i>PLOS Clinical Trials</i> , 2006, 1, e29. | 3.5 | 124 |
| 212 | Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified <i>Vaccinia Virus Ankara</i> Encoding the Full-Length <i>Plasmodium falciparum</i> Circumsporozoite Protein. <i>Infection and Immunity</i> , 2006, 74, 2706-2716. | 1.0 | 62 |
| 213 | Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage <i>Plasmodium falciparum</i> Correlate with Parasitological and Clinical Outcomes. <i>Journal of Immunology</i> , 2006, 177, 5736-5745. | 0.4 | 138 |
| 214 | Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 + T cell responses. <i>Immunology and Cell Biology</i> , 2005, 83, 307-312. | 1.0 | 49 |
| 215 | Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. <i>Hepatology</i> , 2005, 41, 1383-1390. | 3.6 | 125 |
| 216 | Calculation of Liver-to-Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. <i>Journal of Infectious Diseases</i> , 2005, 191, 619-626. | 1.9 | 152 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers. <i>Journal of Immunology</i> , 2005, 174, 449-455. | 0.4 | 143 |
| 218 | Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. <i>Journal of Immunology</i> , 2005, 175, 7264-7273. | 0.4 | 89 |
| 219 | Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. <i>Journal of Immunology</i> , 2005, 175, 5675-5680. | 0.4 | 123 |
| 220 | Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4836-4841. | 3.3 | 228 |
| 221 | Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. <i>Vaccine</i> , 2005, 23, 857-864. | 1.7 | 72 |
| 222 | Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2005, 175, 599-606. | 0.4 | 60 |
| 223 | QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-198. | 0.6 | 96 |
| 224 | Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-8. | 0.6 | 71 |
| 225 | A <i>Plasmodium falciparum</i> candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 290-295. | 3.3 | 59 |
| 226 | Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. <i>Nature Medicine</i> , 2004, 10, 1240-1244. | 15.2 | 538 |
| 227 | Quantitative Association Tests of Immune Responses to Antigens of <i>Mycobacterium Tuberculosis</i> : A Study of Twins in West Africa. <i>Twin Research and Human Genetics</i> , 2004, 7, 578-588. | 1.5 | 3 |
| 228 | Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. <i>Nature Medicine</i> , 2003, 9, 729-735. | 15.2 | 536 |
| 229 | Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against <i>M. Tuberculosis</i> . <i>Clinical Science</i> , 2003, 104, 51P-51P. | 0.0 | 0 |
| 230 | Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. <i>Clinical Science</i> , 2003, 104, 56P-56P. | 0.0 | 0 |
| 231 | EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 421-430. | 0.6 | 34 |
| 232 | Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of <i>Plasmodium falciparum</i> infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 421-30. | 0.6 | 23 |
| 233 | Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. <i>Vaccine</i> , 2002, 20, 1039-1045. | 1.7 | 156 |
| 234 | THE GENOMICS AND GENETICS OF HUMAN INFECTIOUS DISEASES SUSCEPTIBILITY. <i>Annual Review of Genomics and Human Genetics</i> , 2001, 2, 373-400. | 2.5 | 227 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 235 | Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. <i>Lancet</i> , The, 2001, 358, 1927-1934. | 6.3 | 485 |
| 236 | Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. <i>Infection and Immunity</i> , 2001, 69, 681-686. | 1.0 | 213 |
| 237 | Induction of CD8 + T α lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. <i>Immunology and Cell Biology</i> , 2001, 79, 569-575. | 1.0 | 21 |
| 238 | Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. <i>Journal of Medical Virology</i> , 2001, 65, 664-670. | 2.5 | 24 |
| 239 | A major susceptibility locus for leprosy in India maps to chromosome 10p13. <i>Nature Genetics</i> , 2001, 27, 439-441. | 9.4 | 171 |
| 240 | Genetics of susceptibility to human infectious disease. <i>Nature Reviews Genetics</i> , 2001, 2, 967-977. | 7.7 | 447 |
| 241 | High frequencies of circulating IFN- γ -secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. <i>European Journal of Immunology</i> , 2000, 30, 2713-2721. | 1.6 | 94 |
| 242 | Improved method for distinguishing the human source of mosquito blood meals between close family members. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2000, 94, 572-574. | 0.7 | 23 |
| 243 | In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. <i>Nature Medicine</i> , 2000, 6, 337-342. | 15.2 | 521 |
| 244 | Vaccines against intracellular infections requiring cellular immunity. <i>Nature</i> , 2000, 406, 793-798. | 13.7 | 334 |
| 245 | Severe Malarial Anemia and Cerebral Malaria Are Associated with Different Tumor Necrosis Factor Promoter Alleles. <i>Journal of Infectious Diseases</i> , 1999, 179, 287-290. | 1.9 | 231 |
| 246 | Defence by diversity. <i>Nature</i> , 1999, 398, 668-669. | 13.7 | 38 |
| 247 | Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. <i>Immunological Reviews</i> , 1999, 170, 29-38. | 2.8 | 179 |
| 248 | Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. <i>Nature Medicine</i> , 1999, 5, 565-571. | 15.2 | 96 |
| 249 | Potent Induction of Focused Th1 α Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant Plasmodium falciparum Malaria Vaccine. <i>Journal of Infectious Diseases</i> , 1999, 180, 1656-1664. | 1.9 | 148 |
| 250 | The Immunogenetics of Resistance to Malaria. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 272-277. | 2.1 | 54 |
| 251 | Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. <i>Nature Medicine</i> , 1998, 4, 397-402. | 15.2 | 640 |
| 252 | Protection from Plasmodium berghei infection by priming and boosting T α cells to a single class I-restricted epitope with recombinant carriers suitable for human use. <i>European Journal of Immunology</i> , 1998, 28, 4345-4355. | 1.6 | 80 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | Glucose-6-phosphate dehydrogenase deficiency and malaria. <i>Journal of Molecular Medicine</i> , 1998, 76, 581-588. | 1.7 | 210 |
| 254 | THE IMMUNOGENETICS OF HUMAN INFECTIOUS DISEASES. <i>Annual Review of Immunology</i> , 1998, 16, 593-617. | 9.5 | 513 |
| 255 | Protection from <i>Plasmodium berghei</i> infection by priming and boosting T _H 1 cells to a single class I-restricted epitope with recombinant carriers suitable for human use. , 1998, 28, 4345. | | 6 |
| 256 | Heterogeneity of Microsatellite Mutations Within and Between Loci, and Implications for Human Demographic Histories. <i>Genetics</i> , 1998, 148, 1269-1284. | 1.2 | 154 |
| 257 | Genetic analysis of host-parasite coevolution in human malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1997, 352, 1317-1325. | 1.8 | 70 |
| 258 | A protein particle vaccine containing multiple malaria epitopes. <i>Nature Biotechnology</i> , 1997, 15, 1280-1284. | 9.4 | 153 |
| 259 | Heterozygote advantage for HLA class-II type in hepatitis B virus infection. <i>Nature Genetics</i> , 1997, 17, 11-12. | 9.4 | 291 |
| 260 | A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. <i>Immunogenetics</i> , 1997, 45, 229-232. | 1.2 | 15 |
| 261 | T-cell receptor variable alpha (TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations. <i>Immunogenetics</i> , 1997, 47, 124-130. | 1.2 | 5 |
| 262 | Genetic susceptibility to multifactorial diseases. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 369-371. | 0.7 | 1 |
| 263 | Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. <i>BMJ: British Medical Journal</i> , 1997, 315, 96-97. | 2.4 | 66 |
| 264 | Cytotoxic T lymphocytes to <i>Plasmodium falciparum</i> epitopes in an area of intense and perennial transmission in Tanzania. <i>European Journal of Immunology</i> , 1996, 26, 773-779. | 1.6 | 54 |
| 265 | Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. <i>European Journal of Immunology</i> , 1996, 26, 1951-1959. | 1.6 | 89 |
| 266 | HIV and HLA: Confusion or complexity?. <i>Nature Medicine</i> , 1996, 2, 395-396. | 15.2 | 34 |
| 267 | Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. <i>European Journal of Immunology</i> , 1995, 25, 1783-1787. | 1.6 | 44 |
| 268 | Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. <i>Nature Medicine</i> , 1995, 1, 374-375. | 15.2 | 62 |
| 269 | Variation in the TNF- α promoter region associated with susceptibility to cerebral malaria. <i>Nature</i> , 1994, 371, 508-511. | 13.7 | 1,169 |
| 270 | Maintenance of MHC polymorphism. <i>Nature</i> , 1992, 355, 403-403. | 13.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 271 | Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature, 1992, 360, 434-439. | 13.7 | 638 |
| 272 | Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600. | 13.7 | 1,494 |
| 273 | Human genetic susceptibility to infectious disease. , 0, . | | 1 |
| 274 | New Malaria Vaccines: The DNA-MVA Prime-Boost Strategy. , 0, , 87-96. | | 0 |
| 275 | Production of a high purity, C tagged Hepatitis B surface Antigen fusion protein VLP vaccine for malaria expressed in <i>Pichia pastoris</i> under cGMP conditions. Biotechnology and Bioengineering, 0, , . | 1.7 | 1 |